)
Natera (NTRA) investor relations material
Natera Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Quarterly performance and market opportunity
Record quarter for Signatera growth and strong organic gross margin performance; ASPs rose sequentially for Signatera. Revenue grew 42% YoY ex-true-ups, with FY 2026 guidance reset to above $3B.
Signatera’s estimated annual revenue opportunity is ~$20B, with roughly $1B reached to date; FIND-CRC could double the addressable market in the relative near term.
Leadership transition
After eight years as CEO and 16 years at the business, Steve is stepping away; Solomon Moshkevich, a long-tenured leader across Signatera and other operations, is succeeding him.
The transition was described as friendly, with Steve available for a warm handoff; leadership continuity supports readiness for 2027.
Revenue ambition and reimbursement
The $6B-plus 2029 revenue target starts from roughly $3B in 2026 and assumes continued execution, including modest growth in women’s health and transplant and continued Signatera patient growth.
Signatera ASP of $1,450 is a 2029 goal versus a current range of ~$1,290-$1,450; achieving it depends on execution and positive clinical-trial readouts.
Nine Signatera MolDX applications are in flight; broader Medicare and Medicare Advantage tumor coverage could add $200-$300 to ASP, with finalized MolDX responses typically taking 9-12 months.
Further reimbursement levers include Medicare Advantage compliance, commercial coverage in biomarker states, and potential NCCN guideline adoption in colorectal and breast cancer over the next three years.
- A $6B 2029 target builds on Signatera growth, with screening and Japan extending the runway.NTRA
UBS Global Healthcare Conference - A $6B 2029 target and expanding cancer-testing opportunity frame the outlook.NTRA
8th Annual Wolfe Research Healthcare Conference - Revenue grew 34% as volumes climbed, lifting FY2026 guidance and supporting a $6B 2029 target.NTRA
Q3 2026 - Record growth, expanding global reach, and innovation drive strong financial and operational results.NTRA
2026 Global Healthcare Conference - Record MRD growth, expanding biopharma ties, and innovation set the stage for sustained expansion.NTRA
Morgan Stanley 24th Annual Global Healthcare Conference - Record Q2 growth, product innovation, and global expansion drive strong outlook.NTRA
Canaccord Genuity's 46th Annual Growth Conference - Revenue up 38% to $753M, record test volumes, improved margins, and raised guidance.NTRA
Q2 2026 - Record growth, innovation, and AI-driven strategies are accelerating adoption and market expansion.NTRA
Morgan Stanley 23rd Annual Global Healthcare Conference - Record growth, innovation, and clinical momentum set the stage for major milestones in 2025.NTRA
43rd Annual J.P. Morgan Healthcare Conference 2025
)
)
)
)
)
)
)
)